defibrotide and Hypertension

defibrotide has been researched along with Hypertension* in 2 studies

Other Studies

2 other study(ies) available for defibrotide and Hypertension

Article	Year
[Transcutaneous oximetry in smokers with moderate hypertension and peripheral arterial disease treated with amlodipine and defibrotide, also with total smoking cessation]. Minerva cardioangiologica, 1995, Volume: 43, Issue:10 To evaluate the hemorheological influence on oxygen release after a period of 4 months of suspension from smoking and of antihypertensive treatment with amlodipine 10 mg o.d. and defibrotide 400 mg o.d. we have studied 14 smokers with II moderate hypertension (according to the World Health Organization) with hypertensive retinopathy II and slight left ventricular hypertrophy and II stage type a peripheral arterial disease according to Leriche-Fontaine classification. The total suspension for a period of 4 months from smoking associated with a Ca-antagonist such as amlodipine and an hemorheological, antithrombotic drug such as defibrotide together could bring about an improvement on the treatment of hypertension and a notable reduction in the risks linked to the complications found in hypertensives with PAOD II type a. Topics: Amlodipine; Antihypertensive Agents; Blood Gas Monitoring, Transcutaneous; Blood Viscosity; Calcium Channel Blockers; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Peripheral Vascular Diseases; Polydeoxyribonucleotides; Smoking; Smoking Cessation	1995
Glomerular and vascular lesions in DOCA-salt hypertension: the role of anticoagulation. Clinical and experimental hypertension. Part A, Theory and practice, 1988, Volume: 10, Issue:4 The aim of the present experiments was to determine if anticoagulant and antithrombotic drugs, which protect against hypertension and vascular damage in some models of hypertension, have a similar effect in DOCA-salt hypertension. Unilaterally nephrectomized rats received injections of deoxycorticosterone acetate (DOCA) and 1% saline to drink and were treated with either heparin, defibrotide, low molecular weight (LMW) heparin or vehicle (control) for five and a half weeks. At sacrifice heparin treated rats had decreased hematocrit (p less than 0.001) and prolonged APTT (p less than 0.001). LMW heparin and defibrotide groups did not differ from control animals in either hematocrit or APTT. The systolic blood pressure (SBP) of heparin treated rats at sacrifice was lower than control (p less than 0.05) but, there were no other differences in SBP throughout the course of the experiment. Renal morphology revealed a lower number of glomerular epithelial cell droplets in the heparin group (p less than 0.01) only. Vascular damage did not differ significantly between groups. Topics: Animals; Anticoagulants; Blood Vessels; Desoxycorticosterone; Heparin; Hypertension; Kidney Glomerulus; Male; Polydeoxyribonucleotides; Rats; Rats, Inbred Strains; Sodium Chloride	1988

Article

Year

[Transcutaneous oximetry in smokers with moderate hypertension and peripheral arterial disease treated with amlodipine and defibrotide, also with total smoking cessation].

Minerva cardioangiologica, 1995, Volume: 43, Issue:10

To evaluate the hemorheological influence on oxygen release after a period of 4 months of suspension from smoking and of antihypertensive treatment with amlodipine 10 mg o.d. and defibrotide 400 mg o.d. we have studied 14 smokers with II moderate hypertension (according to the World Health Organization) with hypertensive retinopathy II and slight left ventricular hypertrophy and II stage type a peripheral arterial disease according to Leriche-Fontaine classification. The total suspension for a period of 4 months from smoking associated with a Ca-antagonist such as amlodipine and an hemorheological, antithrombotic drug such as defibrotide together could bring about an improvement on the treatment of hypertension and a notable reduction in the risks linked to the complications found in hypertensives with PAOD II type a.

Topics: Amlodipine; Antihypertensive Agents; Blood Gas Monitoring, Transcutaneous; Blood Viscosity; Calcium Channel Blockers; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Peripheral Vascular Diseases; Polydeoxyribonucleotides; Smoking; Smoking Cessation

1995

Glomerular and vascular lesions in DOCA-salt hypertension: the role of anticoagulation.

Clinical and experimental hypertension. Part A, Theory and practice, 1988, Volume: 10, Issue:4

The aim of the present experiments was to determine if anticoagulant and antithrombotic drugs, which protect against hypertension and vascular damage in some models of hypertension, have a similar effect in DOCA-salt hypertension. Unilaterally nephrectomized rats received injections of deoxycorticosterone acetate (DOCA) and 1% saline to drink and were treated with either heparin, defibrotide, low molecular weight (LMW) heparin or vehicle (control) for five and a half weeks. At sacrifice heparin treated rats had decreased hematocrit (p less than 0.001) and prolonged APTT (p less than 0.001). LMW heparin and defibrotide groups did not differ from control animals in either hematocrit or APTT. The systolic blood pressure (SBP) of heparin treated rats at sacrifice was lower than control (p less than 0.05) but, there were no other differences in SBP throughout the course of the experiment. Renal morphology revealed a lower number of glomerular epithelial cell droplets in the heparin group (p less than 0.01) only. Vascular damage did not differ significantly between groups.

Topics: Animals; Anticoagulants; Blood Vessels; Desoxycorticosterone; Heparin; Hypertension; Kidney Glomerulus; Male; Polydeoxyribonucleotides; Rats; Rats, Inbred Strains; Sodium Chloride

1988